RecruitingPhase 2NCT06458413

Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer

Studying Catastrophic antiphospholipid syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Min Yan, MD
Intervention
Utidelone Capsule Plus Capecitabine(drug)
Enrollment
40 enrolled
Eligibility
18-70 years · FEMALE
Timeline
20242025

Study locations (1)

Collaborators

Beijing Biostar Pharmaceuticals Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06458413 on ClinicalTrials.gov

Other trials for Catastrophic antiphospholipid syndrome

Additional recruiting or active studies for the same condition.

See all trials for Catastrophic antiphospholipid syndrome

← Back to all trials